Aralez Pharmaceuticals

Aralez Bio is a biotechnology company that has developed a proprietary platform for the sustainable, large-scale synthesis of noncanonical amino acids (ncAAs). Using directed evolution and biocatalysis, the company’s enzymatic process allows for the production of over 100 ncAAs in a single step with high enantiopurity and water as the primary byproduct. This technology offers a greener and more efficient alternative to traditional chemical synthesis methods, enabling the expansion of the molecular building block toolbox for various applications in drug discovery and material science.

The company provides these unique building blocks to partners in the pharmaceutical, synthetic biology, and agrochemical sectors to support the development of next-generation peptide therapeutics, sustainable agrochemicals, and advanced materials. By addressing the previous limitations of availability and scalability, Aralez Bio enables organizations to incorporate ncAAs into proteins and other molecules to tune functionality, stability, and performance. Its platform facilitates the transition from early-stage discovery to commercial-scale production, helping teams overcome complex development challenges.